Silexion Therapeutics SLXN

Nasdaq · Biological Products, (No Diagnostic Substances) · $9M
$1.44−12.73%Nov 18 close · Databento
Every report since 2024 →
TradingView’s own chart and price feed. The page’s numbers are end-of-day closes.

Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.

The numbers

fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento
Market cap$9M
Enterprise value$3.1M
Revenue$155,000 +453.6%
True FCF (ex-SBC)$-11.0M −28.6%
Rule of 40-6532.2%
Operating margin-7504.5%
True FCF Yield-119.5%
EPS, diluted$89.61 −97.7%
Modern Valuation (EOD)
Market Cap$9M
Enterprise Value$3.1M
EV / True FCF—
EV / FCF—
EV / Gross Profit—
EV / EBIT—
EV / Sales20.00
P / E (GAAP)—
P / FCF—
P / Oper. CF—
P / Book3.52
Owner & Cash Yields
True FCF Yield-119.5%
FCF Yield-118.0%
Owner Earn. Yield-131.2%
Earnings Yield-129.8%
Shareholder Yield—
Buyback Yield—
Dividend Yield—
Dividend / sh—
Payout Ratio—
FCF / sh$-16.67
EPS (diluted)$89.61
Compounder & Returns
Rule of 40-6532.2%
ROIC—
Cash ROIC (CROIC)—
GP / Assets—
ROE-457.6%
ROA-165.1%
Gross Margin—
Oper. Margin-7504.5%
Net Margin-7685.2%
FCF Margin-6985.8%
True FCF Margin-7072.3%
Quality & Dilution
Cash Conversion—
Accrual Ratio−15.1%
SBC % of FCF—
SBC % of Rev86.5%
Reinvest. Rate—
Sales Growth Y/Y+453.6%
Sales 3Y CAGR—
EPS Growth Y/Y−97.7%
FCF Growth Y/Y−28.6%
FCF 3Y CAGR—
Share Change Y/Y+3098.2%
Balance Sheet & Scale
Revenue (FY)$155,000
Gross Profit (FY)—
Oper. Income (FY)$-11.6M
GAAP Net Income$-11.9M
True FCF (ex-SBC)$-11.0M
Cash & Equiv$6.1M
Total Debt—
Net Cash (Debt)$6.1M
Net Cash % MCap+66.2%
Debt / FCF (yrs)—
Current Ratio2.41649,528 sh
Price & Technicals (EOD)
Perf Week−55.42%
Perf Month+836.28%
Perf Quarter+260.90%
Perf Half Y+171.80%
Perf YTD+127.49%
SMA 20 Dist+94.18%$0.74
SMA 50 Dist+210.14%$0.46
SMA 100 Dist+44.78%$0.99
Window High−71.17%$5.00
Window Low+1222.31%$0.11
RSI (14) · Vol58.31235%v
Income Distribution & Cash Flow ConversionHow every dollar of SLXN revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
REVENUE · 100%$155,000GROSS PROFIT · 100.0%$155,000OPER. INCOME · -7504.5%$-11.6MOPEX · 7504.5%R&D $7.1MNET INCOME · -7685.2%$-11.9M
Where Every $100 of Revenue Goes (FY2025)
Cost of Revenue (COGS)$0 ($0.0 / $100)
R&D Reinvestment$7.1M ($100.0 / $100)
Operating Expenses$4.5M ($100.0 / $100)
Tax & Non-Operating$280,000 ($100.0 / $100)
Net Profit Kept$-11.9M ($0.0 / $100)
Earnings Quality: GAAP Profit → True Owner Cash (FY2025)
GAAP Net Income$-11.9M (-7685.2% margin)
Operating Cash Flow (OCF)$-10.8M(-6980.0% of rev)
Less: Capital Expenditures−$9,000(5.8% of rev)
Standard Free Cash Flow (FCF)$-10.8M(-6985.8% margin)
Less: Stock-Based Comp (SBC)−$134,000
True FCF (Owner Cash ex-SBC)$-11.0M(-7072.3% of rev)

Operating leverage — margins

GrossOperatingNet
0%40%80%-7505%-7685%FY23FY24FY25
Unlocked SEC EDGAR Accounting Statements (USD)All 3 statements · Common-size (% of Revenue / Assets) · YoY growth · Tap any core row to explain
Line Item (USD)FY2023FY2024FY2025YoY ΔCAGRTrend
Income Statement
Research & Development (R&D)$3.7M$5.8M$7.1M+22.8%+38.8%
Total Operating Expenses$4.7M$12.6M$11.6M−7.5%+57.6%
Income Tax Expense$32,000$10,000$3,000−70.0%−69.4%
Diluted Shares7,4934,157132,951+3098.2%+321.2%
Balance Sheet
Cash & Equivalents$4.6M$1.3M$6.1M+378.3%+14.4%
Total Current Assets$5.0M$2.3M$6.6M+195.0%+15.5%
Total Assets$5.3M$2.9M$7.2M+152.0%+17.2%
Total Current Liabilities$2.2M$3.5M$2.8M−21.7%+12.1%
Total Liabilities$2.3M$6.9M$4.6M−32.7%+43.0%
Stockholders' Equity$3.0M$-4.0M$2.6M+165.3%−6.9%
Net Cash / (Net Debt)$4.6M$1.3M$6.1M+378.3%+14.4%
Invested Capital$-1.6M$-5.3M$-3.5M+34.0%—
Cash Flow & Capital Allocation
Depreciation & Amortization (D&A)$45,000$25,000$14,000−44.0%−44.2%
Stock-Based Compensation (SBC)$130,000$5.9M$134,000−97.7%+1.5%
Capital Expenditures (CapEx)$12,000$22,000$9,000−59.1%−13.4%
True FCF (ex-SBC Owner Cash)$-4.7M$-14.3M$-11.0M+23.2%—

Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.

On the Wire

what SLXN did at the next close after each story
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.